The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients

E. Al-Yaseen, P. S. Wells, J. Anderson, J. Martin, M. J. Kovacs

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Data evaluating the safety of using weight-based low-molecular-weight heparin in the treatment of obese patients with acute venous thromboembolism are limited. The product monograph of dalteparin suggests the maximum dose should be limited to 18 000 U subcutaneously once daily. There are no specific data regarding the risk of recurrence or bleeding in patients given dalteparin in a weight-based dose of 200 IU kg-1. We report a retrospective chart review of 193 obese patients who weighed more than 90 kg and who received dalteparin at or near to 200 IU kg-1 actual body weight for 5-7 days for acute venous thromboembolism with 90 day follow-up information. Of the patients, 77% had idiopathic venous thromboembolism, 16% had an underlying malignancy, and 7% had a transient risk factor. Warfarin was initiated within 2 days with a target International Normalized Ratio range of 2.0-3.0. All patients were followed for 12 weeks post diagnosis. Only two patients had a major hemorrhage, 4 and 8 weeks from diagnosis. This study supports the safety of dosing dalteparin based on actual body weight in obese patients.

Original languageEnglish
Pages (from-to)100-102
Number of pages3
JournalJournal of Thrombosis and Haemostasis
Volume3
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Keywords

  • Low-molecular-weight heparin
  • Obesity
  • Treatment
  • Venous thromboembolism

Fingerprint

Dive into the research topics of 'The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients'. Together they form a unique fingerprint.

Cite this